Weigao Orthopedic Clinic (688161): Short-term performance is under pressure, innovation drives to a new peak
Guoxin Securities released a research report on April 9 stating that it gave Weigao Orthopedic (688161.SH) an increase in its holdings. The main reasons for the rating include: 1) the 2023 performance was affected by falling factory prices and channel inv
Weigao Orthopedics (688161) 2023 Performance Review: Short-term performance is under pressure, the company actively optimizes product structure
Weigao Orthopedics (688161) Science and Technology Innovation Board Company Dynamic Research: Gathering gaps ended, performance entered an upward channel
Weigao Orthopedics (688161): Performance under pressure from collection, optimistic about the company's platform-based development
Weigao Orthopedics (688161): Performance is under pressure due to disrupted procurement, optimistic about the long-term development trend of leading orthopedic surgeons
Weigao Orthopedics (688161): Performance is in line with expectations, production line layout is becoming more and more complete
Weigao Orthopedics (688161): Short-term performance is under pressure, leading orthopedic surgeons have significant long-term advantages
Weigao Orthopedics (688161) In-depth Report: Collection Drives Import Substitution and Industrial Upgrading, Extended Mergers and Acquisitions Consolidate Leading Position
Weigao Orthopedics (688161): The promotion of collection affects short-term performance, but an increase in the penetration rate of medium- to long-term company products can be expected
Weigao Orthopedics (688161): Innovation continues to lead the development of the industry and build a world-class orthopedic device enterprise
Weigao Orthopedics (688161): Net profit returned to the mother in the first half of the year increased nearly 8% year-on-year, and second-quarter results quickly recovered
Weigao Orthopedics (688161): Quarterly performance marginal improvement, actively opening up new fields of orthopedics
Weigao Orthopedics (688161): Performance exceeds expectations and actively optimizes the marketing system
Weigao Orthopaedics (688161): rapid recovery in the second quarter is optimistic about the increase in postharvest market share.
Vega Orthopaedics (688161): collection has a marginal improvement on the company's actual impact or slightly better than expected quarterly results.
Weigao Orthopedics (688161) Annual Review Report: Orthopedic King's Transformation to “Digital, Intelligent, and Minimally Invasive” Innovation
Vegao Orthopaedics (688161): high-speed growth of main business, trauma collection, excellent performance and stable position.
Weigao Orthopaedics (688161) 2021 report comment: the performance is in line with our expectation that the domestic orthopaedics leader is strong.
Vegor Orthopaedics (688161): Q2 performance slightly exceeded expectations, waiting for collection boots to land
No Data